Unique Glycoform-Dependent Monoclonal Antibodies for Mouse Mucin 21

Mucin 21(Muc21)/epiglycanin is expressed on apical surfaces of squamous epithelia and has potentially protective roles, which are thought to be associated with its unique glycoforms, whereas its aberrant glycosylation is implicated in the malignant behaviors of some carcinomas. Despite the importance of glycoforms, we lack tools to detect specific glycoforms of mouse Muc21. In this study, we generated two monoclonal antibodies (mAbs) that recognize different glycoforms of Muc21. We used membrane lysates of Muc21-expressing TA3-Ha cells or Chinese hamster ovary (CHO)-K1 cells transfected with Muc21 as antigens. Specificity testing, utilizing Muc21 glycosylation variant cells, showed that mAb 1A4-1 recognized Muc21 carrying glycans terminated with galactose residues, whereas mAb 18A11 recognized Muc21 carrying sialylated glycans. mAb 1A4-1 stained a majority of mouse mammary carcinoma TA3-Ha cells in vitro and in engrafted tumors in mice, whereas mAb 18A11 recognized only a subpopulation of these. mAb 1A4-1 was useful in immunohistochemically detecting Muc21 in normal squamous epithelia. In conclusion, these mAbs recognize distinct Muc21 epitopes formed by combinations of peptide portions and O-glycans.

[1]  T. Irimura,et al.  Mucin 21 confers resistance to apoptosis in an O-glycosylation-dependent manner , 2022, Cell death discovery.

[2]  A. Mercurio,et al.  O-linked α2,3 sialylation defines stem cell populations in breast cancer , 2022, Science advances.

[3]  T. Irimura,et al.  A Possible Inhibitory Role of Sialic Acid on MUC1 in Peritoneal Dissemination of Clear Cell-Type Ovarian Cancer Cells , 2021, Molecules.

[4]  T. Irimura,et al.  Mucin 21 is a key molecule involved in the incohesive growth pattern in lung adenocarcinoma , 2019, Cancer science.

[5]  T. Irimura,et al.  Specific expression of MUC21 in micropapillary elements of lung adenocarcinomas – Implications for the progression of EGFR-mutated lung adenocarcinomas , 2019, PloS one.

[6]  Y. Takeshima,et al.  Mucin 21 is a novel, negative immunohistochemical marker for epithelioid mesothelioma for its differentiation from lung adenocarcinoma , 2019, Histopathology.

[7]  S. Batra,et al.  Pathobiological implications of mucin glycans in cancer: Sweet poison and novel targets. , 2015, Biochimica et biophysica acta.

[8]  Guosheng Feng,et al.  Expression profile of mucin-associated sialyl-Tn antigen in Chinese patients with different colorectal lesions (adenomas, carcinomas). , 2015, International journal of clinical and experimental pathology.

[9]  S. Pinho,et al.  Glycosylation in cancer: mechanisms and clinical implications , 2015, Nature Reviews Cancer.

[10]  R. Vitorino,et al.  Overexpression of tumour‐ssociated carbohydrate antigen sialyl‐Tn in advanced bladder tumours , 2013, Molecular oncology.

[11]  C. Landen,et al.  ST6Gal-I sialyltransferase confers cisplatin resistance in ovarian tumor cells , 2013, Journal of Ovarian Research.

[12]  H. Wandall,et al.  Aberrantly glycosylated MUC1 is expressed on the surface of breast cancer cells and a target for antibody-dependent cell-mediated cytotoxicity , 2013, Glycoconjugate Journal.

[13]  T. Irimura,et al.  Mucin 21 in esophageal squamous epithelia and carcinomas: analysis with glycoform-specific monoclonal antibodies. , 2012, Glycobiology.

[14]  H. Nakanishi,et al.  Different Levels of Sialyl-Tn Antigen Expressed on MUC16 in Patients With Endometriosis and Ovarian Cancer , 2011, International Journal of Gynecologic Cancer.

[15]  Z. Yang,et al.  Alpha2,3-Sialylation regulates the stability of stem cell marker CD133. , 2010, Journal of biochemistry.

[16]  T. Itoh,et al.  Mucin 21/Epiglycanin Modulates Cell Adhesion , 2010, The Journal of Biological Chemistry.

[17]  Hongmei Shen,et al.  MCF7 side population cells with characteristics of cancer stem/progenitor cells express the tumor antigen MUC1. , 2008, Cancer research.

[18]  T. Irimura,et al.  Identification and expression of human epiglycanin/MUC21: a novel transmembrane mucin. , 2007, Glycobiology.

[19]  I. Brockhausen,et al.  Mucin‐type O‐glycans in human colon and breast cancer: glycodynamics and functions , 2006, EMBO reports.

[20]  M. Hollingsworth,et al.  Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance. , 2006, Glycobiology.

[21]  P. Stanley,et al.  Lectin-resistant CHO glycosylation mutants. , 2006, Methods in enzymology.

[22]  I. Brockhausen,et al.  Sialylated core 1 based O-linked glycans enhance the growth rate of mammary carcinoma cells in MUC1 transgenic mice. , 2004, International journal of oncology.

[23]  Yoshiyuki Ito,et al.  Purification and properties of recombinant β-galactosidase from Bacillus circulans , 1998, Glycoconjugate Journal.

[24]  Michael A. Hollingsworth,et al.  Mucins in cancer: protection and control of the cell surface , 2004, Nature Reviews Cancer.

[25]  T. Irimura,et al.  Vaccination of mice with MUC1 cDNA suppresses the development of lung metastases , 2004, Clinical & Experimental Metastasis.

[26]  G. Apodaca,et al.  Clathrin-mediated endocytosis of MUC1 is modulated by its glycosylation state. , 2000, Molecular biology of the cell.

[27]  T. Irimura,et al.  A Novel Monoclonal Antibody Specific for Sialylated MUC1 Mucin , 1996, Japanese journal of cancer research : Gann.

[28]  J. F. Codington,et al.  Epiglycanin--a carcinoma-specific mucin-type glycoprotein of the mouse TA3 tumour. , 1992, Glycobiology.

[29]  Y. Kim,et al.  Inhibition of mucin glycosylation by aryl-N-acetyl-alpha-galactosaminides in human colon cancer cells. , 1989, The Journal of biological chemistry.

[30]  D. Kingsley,et al.  Reversible defects in O-linked glycosylation and LDL receptor expression in a UDP-Gal UDP-GalNAc 4-epimerase deficient mutant , 1986, Cell.

[31]  G. Springer.  T and Tn, general carcinoma autoantigens. , 1984, Science.

[32]  A. G. Cooper,et al.  Loss of strain specificity of the TA3-St subline: evidence for the role of epiglycanin in mouse allogeneic tumor growth. , 1979, Journal of the National Cancer Institute.

[33]  T. Irimura,et al.  Immunochemical and chemical investigations of the structure of glycoprotein fragments obtained from epiglycanin, a glycoprotein at the surface of the TA3-Ha cancer cell. , 1975, Carbohydrate research.

[34]  B. Sanford,et al.  Glycoprotein coat of the TA3 cell. Isolation and partial characterization of a sialic acid containing glycoprotein fraction. , 1972, Biochemistry.

[35]  S. Friberg.  Comparison of an immunoresistant and an immunosusceptible ascites subline from murine tumor TA3. I. Transplantability, morphology, and some physicochemical characteristics. , 1972, Journal of the National Cancer Institute.